Y. Ren

发表

Extramedullary blast crisis of CD 34 + CD 38-leukemia stem cells in chronic myeloid leukemia resistant to tyrosine kinase inhibitors : a report of two cases

Guohua Zhou, H. Tong, Y. Ren, 2016 .

TP53 mutations are associated with very complex karyotype and suggest poor prognosis in newly diagnosed myelodysplastic syndrome patients with monosomal karyotype

Jie Jin, Yingwan Luo, Shuanghong Zhu, 2020, Asia-Pacific journal of clinical oncology.

Impact of mutational variant allele frequency on prognosis in myelodysplastic syndromes.

Jie Jin, Yingwan Luo, Shuanghong Zhu, 2020, American journal of cancer research.

Clinical Characteristics and Outcomes of Tuberculosis Infection in Adult Patients with MDS

Yingwan Luo, Shuanghong Zhu, Haiyang Yang, 2020 .

Decitabine combined with low dose idarubicin and cytarabine (D-IA) followed by allo-HSCT improves acute myeloid leukemia and higher-risk myelodysplastic syndrome patient outcomes: results from a retrospective study

Jie Jin, Xinping Zhou, C. Mei, 2021, Leukemia & lymphoma.

Tigecycline and homoharringtonine synergistically target myeloid leukemia cells by inhibiting mitochondrial translation through mTOR/4EBP1 pathway

Jian Huang, Haiyang Yang, Hua Zhang, 2020 .

All-trans retinoic acid enhances the cytotoxic effect of decitabine on myelodysplastic syndromes and acute myeloid leukaemia by activating the RARα-Nrf2 complex

Xiaozhen Liu, P. Lin, Yingwan Luo, 2022, British Journal of Cancer.

Successful treatment of Candida tropicalis osteomyelitis with Micafungin in a leukemia patient

Xinping Zhou, Liya Ma, H. Tong, 2016, IDCases.

Clinical characteristics of T-cell lymphoma associated with hemophagocytic syndrome: Comparison of T-cell lymphoma with and without hemophagocytic syndrome

Jian Huang, Jie Jin, W. Qian, 2008, Leukemia & lymphoma.

Whole exome sequencing reveals a novel LRBA mutation and clonal hematopoiesis in a common variable immunodeficiency patient presented with hemophagocytic lymphohistiocytosis

Xinping Zhou, H. Tong, Jianping Lan, 2021, Experimental Hematology & Oncology.

Homoharringtonine affects the JAK2‐STAT5 signal pathway through alteration of protein tyrosine kinase phosphorylation in acute myeloid leukemia cells

Jie Jin, H. Tong, Y. Ren, 2008, European journal of haematology.

Predictive values of mutational variant allele frequency in overall survival and leukemic progression of myelodysplastic syndromes

Jie Jin, Yingwan Luo, Shuanghong Zhu, 2022, Journal of Cancer Research and Clinical Oncology.

Mutation status and burden can improve prognostic prediction of patients with lower‐risk myelodysplastic syndromes

Jie Jin, Yingwan Luo, Shuanghong Zhu, 2019, Cancer science.

PP2A inhibition from LB100 therapy enhances daunorubicin cytotoxicity in secondary acute myeloid leukemia via miR-181b-1 upregulation

Jie Jin, Z. Zhuang, D. Maggio, 2017, Scientific Reports.

Clinicopathological study on peripheral T-cell non-Hodgkin lymphoma with bone marrow involvement: a retrospective analysis from China

Jie Jin, W. Qian, H. Tong, 2009, International journal of hematology.

Analysis of clinical and molecular features of MDS patients with complex karyotype in China.

Jie Jin, P. Lin, Yingwan Luo, 2019, Blood cells, molecules & diseases.

Clinical and biological characteristics of acute myeloid leukemia with 20–29% blasts: a retrospective single-center study

Jie Jin, P. Lin, Yingwan Luo, 2018, Leukemia & lymphoma.

Isocitrate dehydrogenase 2 mutations correlate with leukemic transformation and are predicted by 2-hydroxyglutarate in myelodysplastic syndromes

Jie Jin, Chao Hu, Weilai Xu, 2018, Journal of Cancer Research and Clinical Oncology.

Decitabine for myelodysplastic syndromes: dose comparison in a real world clinical setting

Jie Jin, Fangjing Shi, P. Lin, 2019, Leukemia & lymphoma.

Decitabine improves overall survival in myelodysplastic syndromes-RAEB patients aged ≥60 years and has lower toxicities: Comparison with low-dose chemotherapy.

Jie Jin, Yingwan Luo, Chao Hu, 2019, Blood cells, molecules & diseases.

Decitabine priming prior to low-dose chemotherapy improves patient outcomes in myelodysplastic syndromes-RAEB: a retrospective analysis vs. chemotherapy alone

Jie Jin, W. Qian, P. Lin, 2017, Journal of Cancer Research and Clinical Oncology.

The high NRF2 expression confers chemotherapy resistance partly through up-regulated DUSP1 in myelodysplastic syndromes

Jie Jin, Xiaomei Yan, M. Azam, 2018, Haematologica.

Diagnosis and management of acquired thrombotic thrombocytopenic purpura in southeast China: a single center experience of 60 cases

Jian Huang, Jie Jin, W. Qian, 2016, Frontiers of Medicine.

Empirical polymyxin B therapy in febrile neutropenic patients with hematological diseases: A prospective, multicenter, observational clinical study.

Jianping Shen, Chao Hu, Xinping Zhou, 2023, The Journal of infection.

Venetoclax plus ‘2 + 5’ modified intensive chemotherapy with daunorubicin and cytarabine in fit elderly patients with untreated de novo acute myeloid leukaemia: a single‐centre retrospective analysis

Min Yang, Yungui Wang, Liya Ma, 2022, British Journal of Haematology.

Real‐world data of chronic myelomonocytic leukemia: A chinese single‐center retrospective study

Jie Jin, P. Lin, Yingwan Luo, 2021, Cancer medicine.

The relation of SF3B1 mutation and intracellular iron in myelodysplastic syndrome with less than 5% bone marrow blasts

Yingwan Luo, Yanling Ren, Xinping Zhou, 2018, Leukemia & lymphoma.

15‐days duration of venetoclax combined with azacitidine in the treatment of relapsed/refractory high‐risk myelodysplastic syndromes: A retrospective single‐center study

Yingwan Luo, Haiyang Yang, Xinping Zhou, 2022, Hematological oncology.

Diffuse large B-cell lymphoma in colon confounded by prior history of colorectal cancer: A case report and literature review.

Zhilu Chen, W. Qian, H. Tong, 2016, Oncology letters.

Epigenetic priming with decitabine followed by low dose idarubicin and cytarabine in acute myeloid leukemia evolving from myelodysplastic syndromes and higher‐risk myelodysplastic syndromes: a prospective multicenter single‐arm trial

Jie Jin, Yue-min Kuang, Yanling Ren, 2020, Hematological oncology.

DUSP1 Signaling Pathway Regulates Cytarabine Sensitivity in Acute Myeloid Leukemia

P. Lin, Xinping Zhou, Chumeng Zhu, 2023, Technology in cancer research & treatment.

Isocitrate dehydrogenase 2 mutations correlate with leukemic transformation and are predicted by 2-hydroxyglutarate in myelodysplastic syndromes

Jie Jin, Z. Zhuang, P. Lin, 2018, Journal of Cancer Research and Clinical Oncology.

Epigenetic priming with decitabine followed by low-dose idarubicin/cytarabine has an increased anti-leukemic effect compared to traditional chemotherapy in high-risk myeloid neoplasms

Jian Huang, Jie Jin, Chao Hu, 2016, Leukemia & lymphoma.

Clinical significance of cytogenetic and molecular genetic abnormalities in 634 Chinese patients with myelodysplastic syndromes

Jie Jin, P. Lin, Yingwan Luo, 2021, Cancer medicine.

RIPK3 deficiency blocks R-2-hydroxyglutarate–induced necroptosis in IDH-mutated AML cells

Yingwan Luo, Shuanghong Zhu, Xinping Zhou, 2024, Science advances.

Co‐mutation landscape and clinical significance of RAS pathway related gene mutations in patients with myelodysplastic syndrome

Yingwan Luo, Xinping Zhou, C. Mei, 2022, Hematological oncology.

Lower-dose decitabine improves clinical response compared with best supportive care in lower-risk MDS patients: a prospective, multicenter phase 2 study

Xinping Zhou, C. Mei, Liya Ma, 2021, Journal of Cancer.